Navigation Links
Rare parasitic fungi could have anti-flammatory benefits
Date:11/14/2012

Caterpillar fungi (Cordyceps) are rare parasites found on hibernating caterpillars in the mountains of Tibet. For centuries they have been highly prized as a traditional Chinese medicine - just a small amount can fetch hundreds of pounds.

Scientists at The University of Nottingham have been studying how this fungus could work by studying cordycepin, one of the drugs found in these mushrooms. They have already discovered that cordycepin has potential as a cancer drug. Their new work indicates that it could also have anti-inflammatory characteristics with the potential to help sufferers of asthma, rheumatoid arthritis, renal failure and stroke damage.

The research, published today in the academic journal RNA, was led by Dr Cornelia de Moor in the School of Pharmacy. It shows that cordycepin reduces inflammatory gene products in airway smooth muscle cells the cells that contract during an asthma attack.

Several studies have suggested that cordycepin could be an effective drug for a variety of conditions, including cancer, stroke, kidney damage and inflammatory lung disease but until now it was unclear how cordycepin could bring about so many different beneficial effects at the cellular level.

Dr de Moor said: "We have shown that cordycepin reduces the expression of inflammatory genes in airway smooth muscle cells by acting on the final step in the synthesis of their messenger RNAs (mRNAs) which carry the chemical blueprint for the synthesis of proteins. This process is called polyadenylation. Commonly used anti-inflammatory drugs either work much earlier in the activation of inflammatory genes, such as prednisone, or work on one of the final products of the inflammatory reaction (e.g. ibuprofen).These findings indicate that cordycepin acts by a completely different mechanism than currently used anti-inflammatory drugs, making it a potential drug for patients in which these drugs don't work well.

"However, it is a surprise that cordycepin does not affect the synthesis of mRNAs from other genes, because nearly all mRNAs require polyadenylation."

Dr de Moor's research suggests that this is because inflammatory genes can be very rapidly induced and that cordycepin has its many and varied effects by altering the synthesis of other classes of rapidly induced genes as well. If this is true if could be said that cordycepin slows down the rapid cellular responses to tissue damage and may work by preventing the over-activation of these responses which are associated with conditions such as asthma, rheumatoid arthritis, renal failure, cancer and stroke damage.

However, it also indicates that cordycepin could have adverse effects on normal wound healing and on the natural defences against infectious diseases.

Dr de Moor said: "We are hoping to further investigate which genes are more dependent on polyadenylation than others and why this is the case, as well as test the effect of cordycepin on animal models of disease. Clinical testing of cordycepin is not in our immediate plans, as we think we first have to understand this drug in more detail before we can risk treating patients with it."


'/>"/>

Contact: Lindsay Brooke
lindsay.brooke@nottingham.ac.uk
44-011-595-15751
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Could Hormone Spray Help Men Stay, Not Stray?
2. Stereoscopic mammography could reduce recall rate
3. Could iPads, Kindles Be Just What the Eye Doctor Ordered?
4. Testing pain killers on humans could save money and speed the arrival of new drugs
5. New cells found that could help save peoples sight
6. Could an Aging Face Reflect an Unhealthy Heart?
7. Virtual reality could help people lose weight, fight prejudice
8. Cancer data in the cloud could lead to more effective treatment
9. Research could lead to preeclampsia prevention
10. Could Cholesterol Treatment Fight Repeat Heart Attack?
11. New research suggests standardized booster seat laws could save lives of children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... ... Today, Bright Pink , a national breast and ovarian health non-profit ... proactively at a young age. 1 in 8 women will develop breast cancer ... can save lives-but only if young women are proactive with their health. Bright Pink’s ...
(Date:2/28/2017)... ... 2017 , ... Science-based sleep company Level Sleep ... HCI students, faculty, and alumni can acquire Level Sleep’s unique sleep system in ... community to receive educational content on sleep and proper biomechanics that will empower ...
(Date:2/28/2017)... ... 28, 2017 , ... Las Vegas Skin and Cancer Clinic (LVSCC) is proud ... 10, 2017, 4-7 pm PST. For more than six decades, LVSCC has provided the ... Rancho neighborhood, has been renovated to provide medical and cosmetic dermatological products and services. ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... a healthcare automation intelligence company based in New York. , “Ensuring an intuitive, ... provider’s workflow remains unaltered. Those two fundamental reasons are the reasons this acquisition ...
(Date:2/28/2017)... ... February 28, 2017 , ... The role of females ... from military to civilian life. Body image dissatisfaction is largely unexamined among female ... and greater occurrence of chronic mental health conditions than female civilians. Female veterans ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017  A landmark study led ... MBBS, PhD, FRACS, of  Sydney Heart and Lung ... will be published in the February 28, 2017 issue ... College of Cardiology . According to the study, which involved 37,720 ... surgery technique (anOPCABG) reduced postoperative stroke by ...
(Date:2/27/2017)... TAMPA, Fla. , Feb. 27, ... medical device company focused on developing cerebral embolic ... the members of the FDA,s Circulatory System Devices ... acknowledgement of the need for cerebral protection following ... "The statements shared by this FDA panel support ...
(Date:2/27/2017)... -- Now in its seventh year, the Pharmaceutical ... successful at developing and commercialising innovation. ... The Index can be summarised ... two different companies in early phase, which would make the ... of each company,s performance between 2011 and 2016, the 2017 ranking sees ...
Breaking Medicine Technology: